小分子藥物

Inorganic porous nanofibers with surfaceinterface defects are prepared through humidity-controlled electrospinninghigh-temperature annealing technology. Under the irradiation of light sources of different wavelengths (380~780 nm), the bound electrons stored in the valence band can be excited to the conduction band to form free electrons on the surface of the material, generating different intensities of microcurrents, light sensitivitymicrocurrent changes. Because the "inorganic nanofiber" technology has high uniquenesshigh product compatibility, it can be applied to a wide range of markets.

NCREE has originally developed 5D digital space—on the basis of 3D city modelsconnections of different kinds of sensors around the world— is an online to offline virtual space with a combination of rising 5G technology advantages. Collectingreorganizing various 3D cartographic data with Building Information Modeling (BIM), satellite imagery, UAV 3D modeling, LiDar point cloud data, etc., can increase the diversity of the buildinglandscape. 5D+5G smart city platform would accelerate the 5D smart city to become the digital twin of a real city.

1. CNN model architecture optimization techniques: Propose an Agilev3-L architecture, with a performance index of mAP@50:95FPS:FP16 up to 171.79 2. GOP-mode acceleration scheme for real time inference: employ GOP-modeTRACKING algorithms to enhance the processing rate. 3. Propose a rapid data labeling system HiTag.

This invention is to apply PS1 to treatreverse T2D. The invention can be developed into small-molecule drugs. Those are first-in-class drugs for T2D because its novel anti-diabetic mode of action.

Diabetes is now still an incurable disease. Beta cell failure is one of common causes. No drugs for this failure have been developed. This invention is to developapply PS1 to treatreverse diabetes. PS1 is a first-in-class small-molecule drug, which targets beta cells by improving their survivalfunction. As a result, PS1 can treatreverse diabetes. The anti-diabetic mechanism of

The present invention discloses the germplasm bank of medicinal coral producing new targeted anti-cancer agent and their aquaculture technology platform. The medicinal corals are collected in Kenting, located at the southern tip of Taiwan. In response to the unmet medical needs of new anti-cancer drugs, our research results will provide more diverse types of new drug targets and lead compounds in the "new drug development-new drug discovery and exploration period".